Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)
采用纳米颗粒白蛋白结合紫杉醇联合曲妥珠单抗和帕妥珠单抗进行新辅助化疗，随后使用表柔比星和环磷酰胺治疗可手术的 HER2 阳性原发性乳腺癌：一项多中心 II 期临床试验 (PerSeUS-BC04)
期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-022-01425-2
Futamura, Manabu; Ishihara, Kazuhiro; Nagao, Yasuko; Ogiso, Atsuko; Niwa, Yoshimi; Nakada, Takumi; Kawaguchi, Yoshihiro; Ikawa, Ai; Kumazawa, Iwao; Mori, Ryutaro; Kitazawa, Mai; Hosono, Yoshiki; Kuno, Masashi; Kawajiri, Mana; Nakakami, Akira; Takeuchi, Makoto; Morikawa, Akemi; Tokumaru, Yoshihisa; Katagiri, Yasuo; Asano, Yoshimasa; Mushika, Yoshinori; Shimokawa, Toshio; Matsuhasih, Nobuhisa
